Viral Infections 2021
Home Page Content
We cordially invite you all the participants from all over the world to attend “European Conference on Viral and Infectious Diseases” is going to be held during May 27-28, 2021 in Copenhagen, Denmark. The Conference highlights the theme “Emerging Investigation to Eradicate Infectious Diseases".
Infectious Diseases are disorders caused by organisms such as bacteria, viruses, fungi, or parasites. Infectious diseases may be of water borne, food borne, vector borne, air borne in human beings as well as in plants and animals. Infectious diseases basically emphasize on the pathogenesis of the bacteria and their therapeutic measures, coalesce of branches of Microbiology especially Clinical and Diagnostic Microbiology which deals with the cure and prevention of the Infectious diseases. It represents an increasingly important cause of human morbidity and mortality throughout the world. Vaccine development is thus of great importance in terms of global health.
Who should attend?
Infections and Infectious diseases can be transmitted from animals to people or from one person to another. They can be mild and self-resolve or develop into serious illnesses if left untreated lead to serious illness, long-term consequences or death.
Two contrasting trends are apparent in the infectious disease market. On one hand, the market has witnessed unprecedented growth in the antiviral and vaccine areas since 2010. In particular, the antiviral market has doubled in size—from $20 billion in 2010 to $42 billion in 2017—driven by therapeutic paradigm shifts, especially in the hepatitis C market. On the other hand, there has been a continued decline in the market for systemic antibacterial therapies, with annual revenues dropping from $15 billion in 2010 to $8 billion in 2017, owing to generic competition and limited pipeline innovation. This trend has ultimately contributed to fuelling the political momentum and debate on antimicrobial resistance and raising the awareness on the need to incentivize innovation in antibiotic drug discovery and development.
With a compounded annual growth rate (CAGR) of 3% from 2017– 2022, the infectious disease market is forecast to expand, but more slowly than the overall prescription drug market, for which a CAGR of 6% is expected in the same period. The HIV integrase inhibitor-based class—the leading growth driver—is expected to generate $7.2 billion in additional sales in 2022 compared with 2017, fuelled by Gilead’s (Biktarvy and Genvoya) and GlaxoSmithKline’s (Triumeq) combination therapies. The polyvalent immunoglobulin segment (Shire’s Gammagard and CSL’s Privigen) and pneumococcal vaccines (Pfizer’s Prevnar 13 and Merck & Co.’s Pneumovax) are expected to be the second and third largest therapeutic areas, with 2022 sales of $9.5 billion and $8 billion, respectively.
The global infectious diseases therapeutics market size was valued at USD 46.88 billion in 2016 and is projected to grow at a CAGR of 6.6% during the forecast period. Rising prevalence and increasing expenditure of infectious ailments to boost the penetration rate of treatments of the diseases, rising initiatives for creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for development of new drugs are to be the factors responsible for growth of this market.
The global IVD infectious diseases market size was valued at USD 18.8 billion in 2018. It is likely to exhibit a CAGR of 6.7% from 2018 to 2026. Increasing external funding for research and development (R&D) activities and proactive government initiatives are among the primary growth stimulants for the market.
US is estimated to grow the rate of 3.37% between 2014- 2019. As per the records, 25% of deaths are mainly due to the infectious diseases. Current market trend shows that North America has the global market for infectious diseases therapeutics due to increasing incidence of infectious diseases due to rise in aging population. Followed by North America highest global market is expected in Asia then followed by the Europe in the global infectious diseases therapeutics market. The main reasons behind the highest market of infectious diseases in the above countries are mainly due to large number of patients and due to increase in government funding.